Oyster Point Pharma Submits a Phase 2 Clinical Trial Protocol to Evaluate OC-01 Nasal Spray for Neurotrophic Keratitis (NK)
The submission was made to Oyster Points Investigational New Drug (IND) for OC-01 (varenicline) nasal spray in dry eye disease.
- The submission was made to Oyster Points Investigational New Drug (IND) for OC-01 (varenicline) nasal spray in dry eye disease.
- The OLYMPIA Phase 2 trial is a multi-center, randomized, double-masked, placebo-controlled study that will enroll adult subjects with NK.
- One-half of the adult subjects will receive one dose of OC-01 nasal spray twice daily for eight weeks; the other half will receive a placebo-controlled nasal spray.
- Neurotrophic keratitis is the second of a number of important indications we are evaluating with OC-01 nasal spray, illustrating Oyster Points commitment to treating unmet needs related to ocular surface diseases, said Jeffrey Nau, Ph.D., M.M.S., president and CEO of Oyster Point Pharma.